Lumibird: Photonics revenue up 13.5% over nine months
The laser and photonic technologies specialist, headquartered in Lannion (Côtes-d'Armor), published on October 26, 2026 an activity update covering the first nine months of 2026. The company highlighted a 13.5% increase in photonics revenue over the period. This publication comes just over a month after the half-yearly results of September 21, 2026. On that occasion, the group had described different dynamics according to its activities. Using the term "confirms", the company presents the nine-month figure in continuity with the trends presented at that time.
Photonics revenue up 13.5% over nine months
The key figure in the publication concerns photonics: its revenue increased by 13.5% over the first nine months of 2026, according to the title of Lumibird's press release. The Photonics division's revenue reached €86.8 million over the first nine months of 2026, compared to €76.5 million a year earlier, representing an increase of 13.5% on a reported basis. To put the scale of the activity in perspective, the group had achieved revenue of €225.6 million over the 2025 financial year, according to the annual accounts published on April 7, 2026. This annual total covers all activities and does not constitute a direct comparable to a nine-month cumulative figure.
Defense and cardiovascular medical leading growth in the first half
During the publication of half-yearly results on September 21, 2026, Lumibird had detailed several drivers. The major Defense & Space programs had progressed by 16.5%, to €29.4 million. The Medtech Photonics activity, focused on cardiovascular applications, had posted an increase of 58.3%. The group had also reported an order book at a level it described as historically high, offering it increased visibility over the following months. This order book represents a level, distinct from the rate of order intake for each period. The same document noted points of friction. Environment, Topography and Security activities had declined by 16.2%, to €5.2 million. The Medical division had been affected in the first quarter by logistical and geopolitical disruptions, and posted a decline of 1.7% in the EMEA region. The 13.5% growth published on October 26, 2026 concerns photonics, which positions the group's main driver of progress within this scope.
Analysts expect €250 million in revenue for 2026
In its report on the 2025 financial year, published on April 7, 2026, management had shown confidence in the group's trajectory. Market expectations point in the same direction: according to the consensus noted on October 26, 2026, the three analysts following the stock anticipate on average revenue of €250 million for the 2026 financial year, in a range of €245 to €259 million. This level compares to the €225.6 million achieved in 2025. Consolidated revenue published on October 26, 2026 reached €168.8 million over nine months, up 8.8% on a reported basis. The element established by the press release remains the 13.5% increase in photonics revenue over the first nine months of 2026.
